Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program

Basit Öğe Kaydı
dc.contributor.authorKorten, Volkan
dc.contributor.authorUlusoy, Sercan
dc.contributor.authorZarakolu, Pinar
dc.contributor.authorMete, Birgul
dc.date.accessioned2019-10-27T19:58:35Z
dc.date.available2019-10-27T19:58:35Z
dc.date.issued2007
dc.departmentEge Üniversitesien_US
dc.description.abstractThe Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) Program is a global study that provides antimicrobial susceptibility data in centers prescribing meropenem. The activity of meropenem and 7 broad-spectrum antimicrobials have been examined against 5208 bacterial isolates from 9 Turkish centers between 2000 and 2003. Cumulative susceptibility rates against all species of Enterobacteriaceae combined were ranked as follows: meropenem (99.3%), imipenem (97.6%), cefepime (80.0%), piperacillin-tazobactam (73.6%), ceftazidime (70.3%), ciprofloxacin (70.1%), cefotaxime (66.9%), and tobramycin (67.2%). The production of extended-spectrum beta-lactamases (ESBLs) was detected in 48.7% of Klebsiella pneumoniae and in 19.5% of Escherichia coli isolates. Of ESBL producing K. pneumoniae isolates, 75.7% were resistant to tobramycin, 40.3% to ciprofloxacin, and 48.3% to piperacillin-tazobactam. Only piperacillin/ tazobactam and carbapenems were active against more than 50% of Pseudomonas aeruginosa at the National Committee for Clinical Laboratory Standards-susceptible breakpoint, and the carbapenems were the most active compounds against Acinetobacter spp. These data confirm the continued potency of meropenem against Enterobacteriaceae in units where it is actively being prescribed. (c) 2007 Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.diagmicrobio.2007.06.016en_US
dc.identifier.endpage457en_US
dc.identifier.issn0732-8893
dc.identifier.issue4en_US
dc.identifier.pmid17888609en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage453en_US
dc.identifier.urihttps://doi.org/10.1016/j.diagmicrobio.2007.06.016
dc.identifier.urihttps://hdl.handle.net/11454/41089
dc.identifier.volume59en_US
dc.identifier.wosWOS:000251809600016en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofDiagnostic Microbiology and Infectious Diseaseen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectantibiotic resistance surveillanceen_US
dc.subjectextended-spectrum beta-lactamasesen_US
dc.subjectmultidrug-resistant Acinetobacteren_US
dc.titleAntibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Programen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu